Daniel Sanghoon Shin

10.1k total citations · 2 hit papers
35 papers, 2.8k citations indexed

About

Daniel Sanghoon Shin is a scholar working on Oncology, Rheumatology and Molecular Biology. According to data from OpenAlex, Daniel Sanghoon Shin has authored 35 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Rheumatology and 9 papers in Molecular Biology. Recurrent topics in Daniel Sanghoon Shin's work include Folate and B Vitamins Research (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Child Nutrition and Feeding Issues (4 papers). Daniel Sanghoon Shin is often cited by papers focused on Folate and B Vitamins Research (11 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Child Nutrition and Feeding Issues (4 papers). Daniel Sanghoon Shin collaborates with scholars based in United States, United Kingdom and Australia. Daniel Sanghoon Shin's co-authors include Antoni Ribas, Jesse M. Zaretsky, Davis Y. Torrejon, Giulia Parisi, Robert Damoiseaux, Cristina Puig-Saus, Thomas G. Graeber, Justin D. Saco, Roger S. Lo and Gabriel Abril Rodriguez and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Daniel Sanghoon Shin

33 papers receiving 2.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

2017 1.3k citations Ángel García-Díaz, Daniel Sanghoon Shin et al. Cell Reports profile →
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

2025 20 citations Mysore S. Veena, Daniel Sanghoon Shin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Sanghoon Shin United States	19	1.7k	1.3k	971	324	289	35	2.8k
Caroline Jochéms United States	31	2.2k 1.3×	1.9k 1.5×	812 0.8×	438 1.4×	229 0.8×	83	3.4k
Soizic Garaud Belgium	26	1.3k 0.8×	1.3k 1.0×	578 0.6×	293 0.9×	308 1.1×	64	2.4k
Ines Gütgemann Germany	25	1.1k 0.6×	1.2k 0.9×	1.3k 1.3×	332 1.0×	368 1.3×	60	3.0k
Hiroko Asanuma Japan	32	1.4k 0.8×	782 0.6×	1.2k 1.3×	520 1.6×	406 1.4×	63	2.6k
Wei Yuan China	32	882 0.5×	912 0.7×	1.2k 1.3×	399 1.2×	558 1.9×	106	2.9k
Jianhua Huang China	20	1.0k 0.6×	785 0.6×	723 0.7×	192 0.6×	353 1.2×	41	2.0k
Nicole E. Scharping United States	18	1.4k 0.8×	2.2k 1.7×	1.0k 1.0×	212 0.7×	754 2.6×	26	3.4k
Arta M. Monjazeb United States	34	1.6k 0.9×	1.3k 1.0×	550 0.6×	966 3.0×	268 0.9×	123	3.2k
Pina M. Cardarelli United States	25	1.1k 0.6×	1.1k 0.9×	1.0k 1.1×	146 0.5×	218 0.8×	66	2.9k

Countries citing papers authored by Daniel Sanghoon Shin

Since Specialization

Citations

This map shows the geographic impact of Daniel Sanghoon Shin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Sanghoon Shin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Sanghoon Shin more than expected).

Fields of papers citing papers by Daniel Sanghoon Shin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Sanghoon Shin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Sanghoon Shin. The network helps show where Daniel Sanghoon Shin may publish in the future.

Co-authorship network of co-authors of Daniel Sanghoon Shin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Sanghoon Shin. A scholar is included among the top collaborators of Daniel Sanghoon Shin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Sanghoon Shin. Daniel Sanghoon Shin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Marilene B., Saroj K. Basak, Eri S. Srivatsan, et al.. (2025). Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, single arm trial.. Journal of Clinical Oncology. 43(16_suppl). 6087–6087.

Shin, Daniel Sanghoon, Saroj K. Basak, Mysore S. Veena, et al.. (2024). Enhanced CTLA‐4 blockade anti‐tumor immunity with APG‐157 combination in a murine head and neck cancer. Cancer Medicine. 13(9). e7212–e7212. 1 indexed citations

Saco, Justin D., Edurne Mugarza, Gabriel Abril-Rodríguez, et al.. (2024). CAR-T cell therapy targeting surface expression of TYRP1 to treat cutaneous and rare melanoma subtypes. Nature Communications. 15(1). 1244–1244. 20 indexed citations

Shi, Yijiang & Daniel Sanghoon Shin. (2023). Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on Cancer Therapies including Immunotherapy. Biomolecules. 13(6). 984–984. 12 indexed citations

Kang, James, Albert I. Ko, Jon Mallen‐St. Clair, et al.. (2022). EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1878(1). 188827–188827. 20 indexed citations

Shin, Daniel Sanghoon, Kevin Park, Edward B. Garon, & Steven M. Dubinett. (2022). Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Seminars in Oncology. 49(3-4). 306–318. 18 indexed citations

Kalbasi, Anusha, Kevin Hakimi, Sarah Kremer, et al.. (2020). Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma. Science Translational Medicine. 12(565). 79 indexed citations

Veena, Mysore S., Santanu Raychaudhuri, Saroj K. Basak, et al.. (2020). Dysregulation of hsa-miR-34a and hsa-miR-449a leads to overexpression of PACS-1 and loss of DNA damage response (DDR) in cervical cancer. Journal of Biological Chemistry. 295(50). 17169–17186. 22 indexed citations

Palaskas, Nicolaos, Roksana Shirazi, Daniel Sanghoon Shin, et al.. (2019). Global alteration of T-lymphocyte metabolism by PD-L1 checkpoint involves a block of de novo nucleoside phosphate synthesis. Cell Discovery. 5(1). 62–62. 20 indexed citations

10.

Aluri, Srinivas, et al.. (2019). Substitutions that lock and unlock the proton-coupled folate transporter (PCFT-SLC46A1) in an inward-open conformation. Journal of Biological Chemistry. 294(18). 7245–7258. 5 indexed citations

11.

García-Díaz, Ángel, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.. (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Reports. 19(6). 1189–1201. 1327 indexed citations breakdown →

12.

Ribas, Antoni, Daniel Sanghoon Shin, Jesse M. Zaretsky, et al.. (2016). PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunology Research. 4(3). 194–203. 302 indexed citations

13.

Shin, Daniel Sanghoon, et al.. (2016). Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification. Case Reports in Oncology. 9(2). 298–304. 17 indexed citations

14.

Shin, Daniel Sanghoon & Antoni Ribas. (2015). The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Current Opinion in Immunology. 33. 23–35. 274 indexed citations

15.

Shin, Daniel Sanghoon, et al.. (2014). Metastatic human epidermal growth factor 2 (HER2/neu) amplified breast cancer with acute fulminant hepatitis responding to trastuzumab, pertuzumab and carboplatin. BMJ Case Reports. 2014. bcr2013203400–bcr2013203400. 3 indexed citations

16.

Shin, Daniel Sanghoon, Rongbao Zhao, András Fiser, & David Goldman. (2012). Functional roles of the A335 and G338 residues of the proton-coupled folate transporter (PCFT-SLC46A1) mutated in hereditary folate malabsorption. American Journal of Physiology-Cell Physiology. 303(8). C834–C842. 11 indexed citations

17.

Remo, Benjamin, Jiaxiang Qu, Frank Volpicelli, et al.. (2011). Phosphatase-Resistant Gap Junctions Inhibit Pathological Remodeling and Prevent Arrhythmias. Circulation Research. 108(12). 1459–1466. 98 indexed citations

18.

Zhao, Rongbao, et al.. (2011). Random Mutagenesis of the Proton-coupled Folate Transporter (SLC46A1), Clustering of Mutations, and the Bases for Associated Losses of Function. Journal of Biological Chemistry. 286(27). 24150–24158. 16 indexed citations

19.

Shin, Daniel Sanghoon, Kris M. Mahadeo, Sang Hee Min, et al.. (2011). Identification of novel mutations in the proton-coupled folate transporter (PCFT-SLC46A1) associated with hereditary folate malabsorption. Molecular Genetics and Metabolism. 103(1). 33–37. 35 indexed citations

20.

Mahadeo, Kris M., Ndeye Diop-Bove, Daniel Sanghoon Shin, et al.. (2010). Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption. American Journal of Physiology-Cell Physiology. 299(5). C1153–C1161. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact